Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL). The decision allows the drug’s use for relapsed or refractory CD22-positive ALL in patients who have. Besponsa logo by Pfizer Inc. Filed by SINGH & SINGH LALL & SETHI. The Current Status of this Trademark Brand is Registered.. Recent Academic Work. Asymptotic Results for Configuration Model Random Graphs with Arbitrary Degree Distributions (2010). Learn about the risks & benefits of BESPONSA™, an Rx treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.. The "Besponsa 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed by this. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06)..